Trials / Completed
CompletedNCT03270332
Effect of Inhaled Albuterol in Pulmonary Hypertension
Effect of Inhaled Albuterol on Pulmonary Hemodynamics in Patients With Group 1 Pulmonary Arterial Hypertension on Oral Pulmonary Vasodilator Therapy: A Proof of Concept Study
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 10 (actual)
- Sponsor
- University of Miami · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the present pilot study is to test the hypothesis that in patients with group 1 pulmonary arterial hypertension (PAH) who are on regular oral pulmonary vasodilator therapy, inhaled albuterol causes transient pulmonary vasodilation.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Albuterol | inhalation of 270μg albuterol through a spacer |
| DRUG | Placebo | inhalation of placebo through a spacer |
Timeline
- Start date
- 2017-10-05
- Primary completion
- 2020-07-02
- Completion
- 2020-07-02
- First posted
- 2017-09-01
- Last updated
- 2021-08-30
- Results posted
- 2021-08-30
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03270332. Inclusion in this directory is not an endorsement.